info@flamel.com
 
Historical Earnings
Presentations
SEC Filings
Request Information
E-mail Alerts


Latest News
Medusa®

A Versatile Nano Carrier for the Delivery of Native Proteins

Medusa®, a self-assembled poly-aminoacid nanogel system, is a versatile protein carrier for the development of novel and second-generation long-acting native protein drugs. more info

Micropump® Technologies
From Pediatric to Geriatric Uses

Controlled-release systems permitting either extended (Micropump® I) or both delayed and extended (Micropump® II) delivery of small molecule drugs.

more info

Latest News

Flamel Technologies Corporate Presentation - March 2010
To view the latest presentation, click here.

March 8, 2010
Flamel Technologies Announces Fourth Quarter and Year-End 2009 Results 

A conference call to discuss the earnings is scheduled for 8:30 AM EST on March 09, 2010.
The dial-in number (for investors in the U.S. and Canada) is 1-877-857-6173; the conference ID number is 2453008.
International investors are invited to dial 1 719-325-4888.
Webcast

March 1, 2010
Flamel Technologies Announces Projected Release Date of Fourth Quarter and Annual Results; Conference Call

November 16, 2009
Flamel Technologies Announces Third Quarter 2009 Results;
Additional New Projects; Cash Increases from $45.1 to $48.8 million
A conference call to discuss earnings is scheduled for 8:30 AM EST November 16, 2009.
The dial-in number (for investors in the U.S. and Canada) is 1-800-860-2442; the conference ID number is 435349.
International investors are invited to dial 1 412-858-4600.
Webcast

September 22, 2009
Flamel Technologies to Present at UBS Global Life Sciences Conference – 10 a.m. ET
Webcast

Annual Report 2008 (PDF)
Annual Report 2008 with 20-F (PDF)

Annual Report 2007 (PDF)

Annual Report 2006 (PDF)

Annual Report 2005 (PDF)


Financial Summary

  3 months ended
December 31, 2009 ($000)
12 months ended
December 31, 2009 ($000)
Total Revenue 10,591 42,118
Total Costs and Expenses (16,528) (53,871)
Profit/(loss) from operations (5,937) (11,753)
Net loss (5,697) (11,439)
Cash and Marketable Securities Position $44.1 MM $44.1 MM
Diluted EPS ($ 0.23) ($0.47)
Basic shares outstanding 24.25 MM 24.23 MM
Contact
Charles Marlio
Director of Strategic Planning and Investor Relations

33 avenue du Dr. Georges Levy
69693 Venissieux Cedex
France
Phone: (+33) 472-783-423
marlio@flamel.com

Frederick Simonin
Marketing analyst

33 avenue du Dr. Georges Levy
69693 Venissieux Cedex
France
simonin@flamel.com